Welcome to our dedicated page for Renovorx news (Ticker: RNXT), a resource for investors and traders seeking the latest updates and insights on Renovorx stock.
RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company developing targeted oncology therapies and commercializing RenovoCath®, an FDA‑cleared local drug‑delivery device enabled by its patented Trans‑Arterial Micro‑Perfusion (TAMP™) therapy platform. News about RenovoRx often highlights progress in both its commercial activities and its clinical development programs.
Investors following RNXT news can expect regular updates on the commercialization of RenovoCath as a stand‑alone targeted drug‑delivery device, including adoption trends among cancer centers, repeat purchase orders, and the expansion of institutions approved to purchase the device. Company announcements also describe physician interest and growing clinical demand for localized, arterial drug‑delivery approaches in solid tumors.
Another major news theme is RenovoRx’s ongoing Phase III TIGeR‑PaC trial, which evaluates intra‑arterial gemcitabine (IAG) delivered via RenovoCath in locally advanced pancreatic cancer. Press releases cover clinical milestones, pharmacokinetic and pharmacodynamic sub‑study results, and abstract acceptances and presentations at scientific meetings such as the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI).
RenovoRx news also includes updates on its post‑marketing observational registry study collecting real‑world safety and survival data in solid tumors, as well as its support of investigator‑initiated trials in borderline resectable and metastatic or oligometastatic pancreatic cancer. In addition, the company reports on corporate developments such as Scientific Advisory Board appointments, participation in investor and industry conferences, and capital markets activities disclosed in SEC filings.
For readers tracking RNXT, this news stream provides ongoing insight into how RenovoRx is advancing its TAMP platform, expanding RenovoCath’s commercial footprint, and generating clinical evidence around its drug‑device combination candidate IAG.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.